VIP and myopia: Besides cholinergic antagonists (both nicotinic and muscarinic), several receptor agonists and antagonists are able to suppress myopia development within these models, including dopamine agonists (apomorphine), glucagon and its agonists, retinoic acid derivatives, VIP (vasoactive intestinal peptide), and adenosine antagonists.